Samsung Biologics highlights service innovations across major biotech events in Europe and the U.S.
Samsung Biologics is participating in three major conferences this May to deepen its engagement with industry decision-makers for addressing research, development, and manufacturing needs.
At Swiss Biotech Day, which took place May 4–6 in Basel, Switzerland, Mark Thompson, Director of CDO Sales, discussed the company’s development services. Thompson’s presentation focused on Samsung Biologics’ integrated development strategy that supports smooth continuity into clinical and commercial manufacturing.
PEGS Boston is taking place May 11–15 in Boston, U.S., and Seahee Kim, Director of Organoids Technology, presented on Samsung Organoids and the company’s research services during a luncheon speaking session. Kim discussed how a streamlined transition to process development and manufacturing is made possible through an integrated Samsung Organoids–CDO approach, driven by the predictive evaluation of anticancer drug candidates.
At CDMO Live, taking place May 19–21 in Rotterdam, the Netherlands, Jeff Mason, Vice President of the New Jersey Sales Office, will focus on the company’s accelerated tech transfer timelines. Mason will present a case study of a successful 90-day technology transfer across Samsung Biologics’ internal sites, which leveraged standardized manufacturing platforms and an agile technology transfer framework within a responsive global supply network.
Through its presence at these key industry events, Samsung Biologics reinforces its role as a global leader, consistently aligning with client needs and exploring partnership opportunities.
Samsung Biologics is participating in three major conferences this May to deepen its engagement with industry decision-makers for addressing research, development, and manufacturing needs.
At Swiss Biotech Day, which took place May 4–6 in Basel, Switzerland, Mark Thompson, Director of CDO Sales, discussed the company’s development services. Thompson’s presentation focused on Samsung Biologics’ integrated development strategy that supports smooth continuity into clinical and commercial manufacturing.
PEGS Boston is taking place May 11–15 in Boston, U.S., and Seahee Kim, Director of Organoids Technology, presented on Samsung Organoids and the company’s research services during a luncheon speaking session. Kim discussed how a streamlined transition to process development and manufacturing is made possible through an integrated Samsung Organoids–CDO approach, driven by the predictive evaluation of anticancer drug candidates.
At CDMO Live, taking place May 19–21 in Rotterdam, the Netherlands, Jeff Mason, Vice President of the New Jersey Sales Office, will focus on the company’s accelerated tech transfer timelines. Mason will present a case study of a successful 90-day technology transfer across Samsung Biologics’ internal sites, which leveraged standardized manufacturing platforms and an agile technology transfer framework within a responsive global supply network.
Through its presence at these key industry events, Samsung Biologics reinforces its role as a global leader, consistently aligning with client needs and exploring partnership opportunities.
Share article
Related Content